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Abstract: Even though essential oils (EOs) have been used for therapeutic purposes, there is
now a renewed interest in the antimicrobial properties of phytochemicals and EOs in particular.
Their demonstrated low levels of induction of antimicrobial resistance make them interesting for
bactericidal applications, though their complex composition makes it necessary to focus on the
study of their main components to identify the most effective ones. Herein, the evaluation of the
antimicrobial action of different molecules present in EOs against planktonic and biofilm-forming
Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria was assessed.
The bactericidal mechanisms of the different molecules, as well as their cytocompatibility, were also
studied. Carvacrol, cinnamaldehyde, and thymol exhibit the highest in vitro antimicrobial activities
against E. coli and S. aureus, with membrane disruption the bactericidal mechanism identified.
The addition of those compounds (≥0.5 mg/mL) hampers S. aureus biofilm formation and
partially eliminates preformed biofilms. The subcytotoxic values of the tested EO molecules
(0.015–0.090 mg/mL) are lower than the minimum inhibitory and bactericidal concentrations obtained
for bacteria (0.2–0.5 mg/mL) but are higher than that obtained for chlorhexidine (0.004 mg/mL),
indicating the reduced cytotoxicity of EOs. Therefore, carvacrol, cinnamaldehyde, and thymol are
molecules contained in EOs that could be used against E. coli– and S. aureus–mediated infections
without a potential induction of bactericidal resistance and with lower cell toxicity than the
conventional widely used chlorhexidine.
Keywords: antimicrobial; essential oils; monoterpenoids; cytotoxicity; wound dressings
1. Introduction
Since the discovery of penicillin, the use of antibiotics, originally developed for human healthcare,
has been extended to animal therapeutics and agriculture [1]. The use and misuse of antibiotics has
led to the emergence of antibiotic resistance in human and animal pathogens, which is recognized as
a serious and global concern because resistance in common bacteria has reached alarming levels in
all parts of the world [2]. The continued evolution of antimicrobial resistance (AMR) in hospitals is
a growing concern because of its potential to endanger the future of antimicrobial drug therapy [3].
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Even the new generation of antibiotics is becoming virtually ineffective, and it is predicted that AMR
will cause more deaths than cancer-associated diseases by the middle of the century [4]. The discovery
of strains resistant to all antibiotics available in the clinic has also made an impact on society in
general [5]. Sub-inhibitory antibiotic doses help stepwise selection of resistance, and the resulting
resistant clones like methicillin-resistant Staphylococcus aureus, Escherichia coli, and Klebsiella are rapidly
disseminated. The overall burden of staphylococcal disease caused by methicillin-resistant S. aureus
(MRSA) strains is increasing in many countries in both healthcare and community settings [6].
Multiple antimicrobial resistance determinants have been found in E. coli on the same plasmid,
further facilitating their propagation and co-selection. For instance, the multidrug resistance plasmid
IncA/C found in E. coli, often encodes for resistance to common antimicrobial agents such as
tetracycline, chloramphenicol/florfenicol, streptomycin/spectinomycin, sulfonamides, and extended
spectrum β-lactamases, and its spread to pathogenic bacteria may limit antibacterial means to fight
infections caused by these bacteria [3].
Because of the emergence of AMR, the Center for Disease Control (CDC) has endorsed the need
for the development of new antibiotics. However, the elaboration of new antibiotics is expensive
and time-consuming. Meanwhile, the genetic plasticity in pathogens results in the development
of resistance at a rapid rate [7]. Therefore, there is a crucial need for research of new substances
with the potential to combat resistant strains to minimize their selection. In 2011, academics and
industry collaborated on a priority list for approaches to resolve the “antimicrobial-resistance crisis.”
Amongst the potential strategies suggested, the development of alternatives to antibiotics were
proposed [8]. Compounds from natural sources such as animals, plants, and microorganisms have been
highlighted as renewed potential antimicrobial alternatives [9]. Famous seafarers (e.g., Marco Polo)
established routes for specie trade, and different compounds of natural origin present in species
are still being used today to prevent foodborne pathogens showing low levels of antimicrobial
resistance [10]. Antibiotics by definition have a natural origin (i.e., penicillin is derived from
Penicillium fungi), and antimicrobials of synthetic origin used to fight against infection are considered
as drugs (i.e., isoniazid). However, there are several antibiotics that have multiple mechanisms of
action. In this regard, essential oils (EO) are oily aromatic substances extracted from plants with
antibacterial, antifungal, insecticidal, and antiviral properties. EOs have been distilled for more than
2000 years, and there is now renewed interest in the antimicrobial properties of phytochemicals and
EOs in particular. The demonstrated low levels of induction of antimicrobial resistance toward EOs
could be related to the fact that these substances do not attack a single specific target but have multiple
modes of antibacterial action [1]. Antibiotics, and antiseptics like chlorhexidine, have been shown
to be able to generate resistance in Staphylococcus [11] by mechanisms (mutations in qacA/B gene)
that may be common to other microorganisms. However, EO-based compounds are reported as
unable to generate antimicrobial resistances in studies involving Gram negative and Gram positive
microorganisms subsequently treated with clove, thyme, cinnamon, and oregano oils [12–15].
EOs are complex blends of a variety of molecules such as terpenoids, phenol-derived aromatic
components, and aliphatic components. Their compositions depend on factors such as seasonal
variation, climate, plant organ, age, subspecies, and even the oil extraction method. Consequently,
the extracted product can fluctuate in quality, quantity, and composition [16]. Generally, EOs contain
about 20–60 components, up to more than 100 single substances, at quite different concentrations;
two or three are major components at fairly high concentrations (20–70%) compared to other
components that are present only in trace amounts. Because of this, in order to have a systematic
evaluation of EOs’ antibacterial activity, it is necessary to focus on the study of their main components.
Different extracted components from EOs such as carvacrol, thymol, eugenol, perillaldehyde,
and cinnamaldehyde have been reported as antibacterial agents [17]. However, the reported values
for their minimum inhibitory (MICs) and bactericidal (MBCs) concentrations are extremely divergent.
For example, the MIC of carvacrol toward S. aureus found in the literature ranges from approximately
0.15 mg/mL [18] to 15 mg/mL [19]. In some cases, the different MICs reported could be attributed
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to the bacteria strain used. Wang et al. [20] reported an MIC value for carvacrol of 0.31 mg/mL
for S. aureus ATCC 43300, while using S. aureus ATCC 6538, Silva da Luz et al. [21] reported a MIC
of 2.5 µL/mL (approximately 2.45 mg/mL) for the same component. Even for the same bacteria
strain (ATCC 6538), MIC values for carvacrol of 0.4 mg/mL [22] and 0.015% v/v (approximately
0.147 mg/mL) [18] can be found in the literature.
Beside the well-documented antibacterial action of EO components, there is some evidence
corroborating the enhancement in the antimicrobial action of EO components used in combination with
other antimicrobial agents, both synthetic and natural [23]. Thymol and carvacrol were found to have
additive antibacterial effect against S. aureus, E. coli, Salmonella, and Bacillus cereus. Ye et al. [24] tested
the synergy between cinnamaldehyde and carvacrol in S. aureus and E. coli among other bacteria and
concluded that cinnamaldehyde and carvacrol exhibit high antibacterial activities and have synergistic
antimicrobial action against these bacteria. Thymol and carvacrol were found to give an additive effect
when tested against S. aureus and Pseudomonas aeruginosa [25]. Thymol combined with carvacrol had
a synergistic effect against Salmonella typhimurium [26].
One interesting application of EO components with antimicrobial activity would be their
incorporation into wound dressings since they can prevent or treat wound-associated infections
and aid tissue regeneration [27]. Bacterial components have been highlighted as harmful factors
during wound healing due to their interference with cell-matrix interactions and due a reduced
inflammatory response they produce. In this regard, S. aureus colonize from 30% to 50% of healthy
adults and is able to rapidly infect skin lesions with a consequential inflammatory process [28]. E. coli is
also among the main bacterial species that commonly colonize skin wounds, and from this initial
colonization, severe problems can occur such as topical infections or even sepsis [29]. Within the clinical
settings, biofilm formation is a pressing challenge that leads to chronic infections. Prevention of biofilm
formation is considered preferable to its removal, since the latter is a very difficult and demanding
task, which can cause recontamination problems due to the uncontrolled release of bacterial cells and
toxins after their disruption. One of the outstanding antimicrobial properties of many EOs is that they
can also be effective even against microbial biofilms [30].
The aim of this work was to shed light on the evaluation of the bactericidal activity and mechanisms
of action of EO-present molecules against S. aureus and E. coli in planktonic growth. The antibiofilm
efficiency and the possibility of synergy between carvacrol (CRV), cinnamaldehyde (CIN) and thymol
(THY) were also analyzed. The potential toxicity of those components was also investigated in different
cell types, including human dermal fibroblasts, keratinocytes, and macrophages. The main goal of this
work is to deepen our understanding of the effects and mechanisms of these purified molecules on
bacteria, avoiding the intrinsic variability of their extraction from plants, and focusing on their own ability
to hamper bacteria growth and colonization.
2. Results
2.1. Bactericidal Activity against Planktonic Bacteria
2.1.1. MIC and MBC Values
The antibacterial effect of several components present in different EOs reported as bactericidal,
such as carvacrol [31], thymol [32], cinnamaldehyde [33], eugenol [34], β-caryophyllene [35],
and rosmarinic acid [36], were studied. Squalene, a well-known natural antioxidant [37], was also
included in the study for comparison. Table 1 and Figure S1 show the MIC and MBC results of
the components against E. coli and S. aureus. The most active compounds were THY, CRV, CIN,
and eugenol, showing significant differences against the control sample.
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Table 1. Chemical structure and minimal inhibitory concentration (MIC) and minimal bactericidal
concentration (MBC) values of different essential oil contained compounds. Average of 12 replicas
each compound.
Active Compound Structure
MIC (mg/mL) MBC (mg/mL)
E. coli S. aureus E. coli S. aureus
Carvacrol 0.2 0.2 0.4 0.3
Cinnamaldehyde 0.2 0.4 0.3 0.5
Thymol 0.2 0.2 0.3 0.3
Eugenol 0.4 1.3 0.5 1.5
β-caryophyllene >4.0 >4.0 >4.0 >4.0
Rosmarinic acid >4.0 2.5 >4.0 4.0
Squalene >4.0 >4.0 >4.0 >4.0
2.1.2. Bactericidal Mechanism
E. coli and S. aureus exposed during 24 h to CRV, CIN, and THY at MIC and MBC concentrations
were morphologically examined by scanning electron microscopy (SEM) (Figure 1). The morphology
and microstructure of S. aureus before being exposed to any compound can be observed in Figure 1A,
having a normal and spherical shape and a well-preserved cell membrane. However, after exposition to
CRV, CIN and THY at MICs for 24 h (Figure 1B–G), the morphology of S. aureus was distorted. Part of
the cell peptidoglycan structure appeared depressed, indicating an initial damage. S. aureus exposed
to MBC concentrations during 24 h became deformed and wrinkled, indicating that the intracellular
content had leaked out. There was a reduced number of bacteria in the samples, and it was hard to
find the ones exposed to CIN, probably due to the severe damage to the bacterial peptidoglycan layer
and cell membrane and subsequently cell death and detachment from the filter holder. The reduction
in cell size, length, and diameter observed for S. aureus in response to the active compound could be
reasonably attributed to the leakage of cytosolic fluids outside the cells. E. coli untreated cells were rod
shaped, regular, and with intact morphology (Figure 2A) in contrast to MIC-treated cells (Figure 2B–G).
SEM images showed morphological alterations and lyses of the outer membrane integrity in cells
exposed at MICs. At MBC, a complete lysis or seriously damaged cells were observed.
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Figure 1. Scanning electron microscopy (SEM) images of S. aureus (A) untreated (control sample);
treated bacteria during 24 h with MIC of (B) carvacrol; (D) cinnamaldheyde; (F) thymol; treated bacteria
during 24 h with MBC of (C) carvacrol; (E) cinnamaldheyde; (G) thymol.
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Figure 2. SEM images of E. coli (A) untreated (control sample); treated bacteria during 24 h with MIC of
(B) carvacrol; (D) cinnamaldheyde; (F) thymol; treated bacteria during 24 h with MBC of (C) carvacrol;
(E) cinnamaldheyde; (G) thymol.
In order to confirm the bactericidal mechanism of the active compounds present in EOs, flow
cytometry and confocal microscopy studies were developed. Flow cytometry histograms (Figure S2)
displayed peaks in the range of the negative control (damaged membrane caused by chlorhexidine [38])
when S. aureus and E. coli were treated with the tested compounds at MBC, which is consistent with
cell membrane disruption as previously reported [39]. Only CIN-treated cells show peaks slightly
displaced toward the positive control (undamaged membrane) for both microorganisms, suggesting
that the involvement of cell membrane disruption in bacteria death was not as clear as the SEM
images showed. However, confocal microscopy images (Figure 3 and Figure S3) clearly confirmed
membrane damage exerted by the compounds tested when bacteria were incubated with the MICs of
the molecules, showing red staining related to membrane integrity compromise. Furthermore, in the
case of E. coli, the damaged membrane areas can be clearly distinguished (Figure 3D–F). All these
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results point out to the bacteria membrane disruption as the bactericidal mechanism exerted by the
compounds present in the EOs.
Figure 3. Confocal microscopy images of S. aureus (A–C) and E. coli (D–F) treated with the MIC of
carvacrol (A,D), cinnamaldheyde (B,E) and thymol (C,F), stained with the Live/Dead®BacLight™
bacterial viability kit. Red staining displays membrane damage.
2.1.3. Synergism
Synergistic interactions between EO active compounds may increase their efficacy as antibacterial
agents. In our studies, the Fractional Inhibitory Concentration Index (FICI) values obtained against
S. aureus (Table 2; Figure S4) indicate that only the CRV-THY combination has an additive effect,
while CIN has no interaction with the other compounds tested. These results may be related to their
chemical structure as CRV and THY have almost the same molecular structure (Table 1). It is worth
noting that all the FICI values are smaller than 4.0 indicating that there is no antagonism between the
tested active compounds.
Table 2. Fractional Inhibitory Concentration (FIC) and Fractional Inhibitory Concentration Index (FICI)
values for active compounds combination.
Carvacrol-Cinnamaldehyde Carvacrol-Thymol Thymol-Cinnamaldehyde
FICCRV FICCIN FICI FICCRV FICTHY FICI FICTHY FICCIN FICI
0.7 1.0 1.7 NI 1 0.4 0.5 0.9 ADD 2 0.8 0.4 1.2 NI 1
1 NI: No interaction. 2 ADD: Additive.
2.2. Antibiofilm Activity
S. aureus biofilm formation was observed by calcofluor white staining and by SEM analysis after
incubation for 16 h (Figure 4A,B, respectively). The quantification (colony forming units per milliliter
= CFU/mL) carried out after incubation of the formed biofilm (Figure 5A) with the antimicrobial
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compounds has shown a statistically significant decrease in bacteria growth compared to the untreated
biofilms. At 0.5 mg/mL of EO-contained molecules, preformed biofilms showed a reduction in bacteria
growth around 2 logs when biofilm was treated with CIN, while CRV and THY exerted a superior
decrease (3 logs). The highest tested concentration (1 mg/mL) showed a reduction in CFU/mL higher
than 5 logs. As expected, concentrations of the active molecules higher than MIC and even MBC values
obtained for planktonic bacteria are needed for biofilm elimination.
The addition of these compounds to the bacteria suspension before biofilm formation hindered
this process since there was a significant decrease in the posterior bacterial growth (4 logs for CIN)
(Figure 5B). THY and CRV produced even higher reductions of about 5 and 6 logs, respectively. Again,
the concentrations needed to retard biofilm growth and development were higher than the MIC values
retrieved for planktonic bacteria (Table 1).
Figure 4. Calcofluor staining (A) and SEM images of S. aureus biofilm formed after 16 h (B).
Figure 5. Effect of EOs components at different concentrations on S. aureus biofilm: elimination of
preformed biofilm (A) and inhibition of biofilm formation (B). CTRL = Control sample (not treated
biofilm), CRV = biofilm treated with Carvacrol, CIN = biofilm treated with cinnamaldehyde,
THY = biofilm treated with thymol.
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2.3. Cytotoxicity
Cytocompatibility and not cytotoxicity is required for a wound-healing product since it would be
in contact with the infected wound tissue and its neighboring eukaryotic cells. The cytotoxicity
activities of these antimicrobial compounds were investigated using fibroblasts, macrophages,
and keratinocytes cell lines (Figure 6). Inflammatory cells such as macrophages are generated during
wound healing [40], whereas keratinocytes and fibroblasts are part of the epidermis and dermis,
respectively. Due to the insolubility of those compounds in aqueous media, those were dispersed
using Tween® 80 (Sigma-Aldrich, St. Louis, MO, USA) as described in the materials and methods
section. Hence, the cytotoxicity of the free compounds would be reduced in absence of Tween® 80 due
to their nonpolar character.
Figure 6. Cell viability after treatment with carvacrol, cinnamaldehyde, thymol and chlorhexidine for
24 h on human dermal fibroblasts (A); macrophages (B); keratinocytes (C). Control sample (untreated
cells) = 100% viability.
CIN was the most cytotoxic chemical of the tested molecules; a dose of 0.030 mg/mL of this
compound was enough to reduce the viability of keratinocytes and macrophages below 70% (lowest value
established by the ISO 10993-5 [41] to consider a material as non-cytotoxic), and 0.015 mg/mL affects the
fibroblasts viability (Figure 6). THY and CRV can be considered toxic to fibroblasts at concentrations equal
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or higher than 0.090 mg/mL, and the calculated subcytotoxic doses for keratinocytes were 0.060 and
0.030 mg/mL, respectively. There is also a difference between the effect of THY and CRV on macrophages,
since subcytotoxic concentrations were 0.060 and 0.090 mg/mL, respectively.
Chlorhexidine, a typical disinfectant and antiseptic drug used in skin disinfection, was tested for
comparison. For the studied concentrations (0.004–0.125 mg/mL), chlorhexidine reduces the viability
of the three cellular types to 70% or below. Only fibroblasts show viability higher than 70% in presence
of chlorohexidine at 0.004 mg/mL. For keratinocytes and macrophages, the subcytotoxic concentration
was lower than 0.004 mg/mL.
These subcytotoxic values of the tested compounds were lower than the MICs and MBCs retrieved
for bacteria but higher than those obtained with chlorhexidine. In order to reduce bacterial burden in
wounds, topical antiseptic agents, among them chlorohexidine gluconate, are usually applied as 2 and
4 v/v % topical solutions, concentrations five orders of magnitude higher than the subcytotoxic doses.
Therefore, in our study, the presence of antibacterial compounds of natural origin in a wound dressing
material at MBC concentrations would be only three orders of magnitude higher than the subcytotoxic
dose in the worst case scenario demonstrating that those natural origin compounds are less harmful
against eukaryotic cells than conventional antiseptics.
3. Discussion
Microorganism resistance to antibiotics and antiseptics has become a serious problem in the
treatment of infections and results in the imperative search of novel antibacterial approaches. In this
regard, EO-based compounds have been pointed out as a suitable strategy due to their bactericidal
properties together with their inability to generate antimicrobial resistances [12–15]. Previous studies
have highlighted these promising attributes [17–22] though their complex composition is tightly joined
to different factors (i.e., seasonal variation, age), which means variability in their bactericidal effects.
Thus, in order to delve into EOs antibacterial activity, it is necessary to focus on the study of their
main components.
Our work focuses on the bactericidal effects and the mechanisms of action of purified EO-present
molecules (CRV, CIN, THY), circumventing their intrinsic variability associated to their plant extraction,
against Gram positive (S. aureus) and Gram negative (E. coli) bacteria in order to elucidate their own
ability to kill bacteria. MIC and MBC studies (Table 1 and Figure S1) pointed to THY, CRV, CIN and
eugenol as the most effective studied molecules against E. coli and S. aureus showing the lowest
concentrations to inhibit or hamper planktonic bacteria growth. The bactericidal mechanism of the
most effective EO-derived molecules (CRV, THY, CIN) was assessed by SEM, flow cytometry and
confocal microscopy after treatment of E. coli and S. aureus planktonic cultures at MIC and MBC
concentrations for 24 h (Figures 1–3, Figures S2 and S3). These methodologies pointed to membrane
disruption as the bactericidal mechanism exerted by these molecules. It is known that phenols, terpenes
and aldehydes antibacterial effect is due to their action against the cell cytoplasmic membrane [42].
It has been reported that CRV and THY disturb the membrane integrity, increasing the membrane
permeability and causing a leakage of protons and potassium finally leading to the loss of membrane
potential [43]. Di Pascua et al. [42] suggested that the presence of the hydroxyl group in CAR and THY is
related to the inactivation of the microbial enzymes. This group would interact with the cell membrane
causing leakage of cellular components, a change in fatty acids and phospholipids, and an impairment
of the energy metabolism influencing genetic material synthesis. However, some authors have pointed
out to different bactericidal mechanisms of action for both compounds due to the different location of
the hydroxyl group in their structure affecting cell membrane permeability [44], while others agree
with our results, showing similar effects for both compounds on bacterial membrane structure [45].
It is important to point out that the bactericidal action cannot be related only to the OH group since
eugenol having also a hydroxyl group exhibited lower bactericidal effect (Table 1). According to
the literature, the antibacterial mechanism of CIN is not clear. On one hand, its antimicrobial action
was attributed to the inhibition of the amino acid decarboxylase activity to bind proteins and no
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disintegration of the membrane was observed [24]. However, Nazzaro et al. [42] sustained that
like CRV, CIN inhibits the generation of adenosine triphosphate from dextrose and disrupts the
cell membrane. In addition, the hydrophobicity of the components present in EOs enables their
accumulation in cell membranes disturbing their structures and causing an increase in the permeability
allowing intracellular constituents leakage [43]. Our studies would indicate similar trends in MIC and
MBC values for CRV, THY, and CIN, as well as the disruption of the bacterial surface as target for their
activity by three different experimental techniques analyzed.
On the other hand, synergism between EO active molecules has been shown as more efficient
as bactericidal agents. For instance, polyethylene films containing a mixture of CRV and THY
entrapped within halloysite nanotubes exhibited superior antimicrobial activity against E. coli than
films containing the individual compounds alone [44]. The combination of CIN and CRV showed
better bactericidal effect compared with the components alone against food-borne bacteria [24].
Zhou et al. [26] reported that CIN had a synergistic effect when combined with THY or CRV against
Salmonella typhimurium. However, in our case, FICI data obtained against S. aureus (Table 2 and
Figure S4) pointed to CRV-THY as the most efficient combination displaying an additive effect,
while CIN did not exert any synergism. The synergistic mechanism between CIN with CRV or with
THY was proposed to be caused by the increase in the membrane permeability that enables CIN to be
transported into the cell [24]. But according to the treated bacteria SEM micrographs (Figures 1 and 2),
flow cytometry histograms (Figure S2) and confocal microscopy images (Figure 3 and Figure S3),
the effect of the three compounds against E. coli is mainly outer membrane disintegration and the
morphology of treated S. aureus was similar for the three active compounds. THY and CRV were
previously found to give an additive antimicrobial effect on S. aureus [25], which is in accordance with
its similar chemical structure (Table 1).
S. aureus is involved in a wide range of infections that are difficult to treat because, beside
the frequent occurrence of antimicrobial-resistant strains, S. aureus often resides within biofilms at
the infection site [45]. Biofilms are communities of microorganisms living at an interphase where
they attach to each other through the extracellular polymeric substance also known as the biofilm
matrix composed of extracellular DNA, proteins, and polysaccharides. Due to the protection of
this matrix, bacteria show up to 1000 times greater tolerance to antibiotics and biocides than their
planktonic counterparts [46]. Because of this, it is important to find compounds that interfere with
the early steps of biofilm formation and slow down its formation rate. As expected, concentrations
of the active molecules higher than MIC and even MBC values obtained for planktonic bacteria are
needed for biofilm elimination. Our study shows that concentrations higher than 1 mg/mL of any
of the compounds tested would be necessary for the total elimination of preformed biofilms. Again,
the concentrations needed to retard biofilm growth and development were higher than the MIC values
retrieved for planktonic bacteria (Table 1), but they were in the same range than those reported in
the literature [32].
Regarding the use of these EO-present molecules against bactericidal infections, i.e., chronic
wounds, the evaluation of their cytocompatibility in human cell cultures is advisable. Our study
showed subcytotoxic concentrations between 0.015 and 0.090 mg/mL, pointing to CIN as the
most cytotoxic molecule assayed in human dermal fibroblasts, keratinocytes, and macrophages.
However, the widely used antiseptic chlorhexidine was found more cytotoxic than the EO-based
compounds, displaying a subcytotoxic concentration of 0.004 mg/mL. Previous studies have also
evaluated the toxicity of different compounds present in EOs on different human cell types, such as
fibroblasts [47], intestinal cells [48] or different tumor cell lines [49,50]. Their results show subcytotoxic
concentrations for CRV and THY in the same range as ours (~500 µM) [48] or higher (50% viability at
~5 µg/mL) [47] and also very similar for CIN (~10 µg/mL) [50] pointing to apoptosis and membrane
damage as key cytotoxic mechanisms. Even though the studied molecules showed cytotoxic activity
at doses above 0.06–0.09 mg/mL, it is important to point out that during the regenerative process
in an infected wound the antimicrobial compound at those doses would eradicate both bacteria and
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eukaryotic cells, but while bacteria are removed from the injury, eukaryotic cells are continuously
arriving to the wound to participate in the regenerative process [27]. Hence, only a small fraction of
eukaryotic cells would be damaged.
Finally, the present work has shown the bactericidal effects and mechanisms of promising
antibacterial purified EO-based compounds (CRV, THY, CIN), avoiding the variability of plant extracted
compounds, for their incorporation to different clinical treatments, i.e., wound dressings for chronic
wounds. Their efficiency against both planktonic and biofilm bacteria highlights their potential to
be included in bactericidal approaches in order to develop novel strategies against antibiotic and
antiseptic resistance.
4. Materials and Methods
4.1. Materials
Carvacrol (CRV), cinnamaldehyde (CIN), thymol (THY), Squalene, Rosmarinic acid, β-Caryophyllene,
Calcofluor White Stain, phorbol 12-myristate 13-acetate (PMA), and Tween® 80 were purchased from
Sigma-Aldrich (St. Louis, MO, USA), while Eugenol was supplied by Acros Organics (Gell, Belgium).
Tryptone soy broth (TSB) and agar (TSA) were obtained from Conda-Pronadisa (Madrid, Spain) and S. aureus
(ATCC 25923) from Ielab (Alicante, Spain). Regarding cell lines, human dermal fibroblasts were purchased
from Lonza (Bornem, Belgium), and THP1 human monocytes (ATCC TIB-202) from LGC Standards
(Barcelona, Spain), while human keratinocytes were kindly gifted by Dr Pilar Martín-Duque. High-glucose
DMEM (DMEM w/stable glutamine), RPMI 1640 w/stable glutamine, and antibiotic-antimycotic (60µg/mL
penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B) were supplied by Biowest
(CEDEX, France). Cell culture reagents, such as fetal bovine serum (FBS), HEPES, nonessential amino acids,
2-mercaptoethanol 50 mM and sodium pyruvate 100 mM, were obtained from Gibco (Manchester, UK),
and the Blue Cell Viability assay from Abnova (Aachen, Germany).
4.2. Bacteria Culture
A Gram-negative model E. coli S17 strain was used, which was kindly donated by Dr. Jose Antonio Ainsa,
exerting resistance to streptomycin as it is also widely used for transformation purposes [51]. S. aureus
ATCC 25923, well-known as not a resistant strain and used in susceptibility tests [52,53], was evaluated
as a Gram-positive model. Both strains were initially grown overnight in TSB at 37 ◦C under shaking
(150 rpm) obtaining, in the stationary growth phase, 108–109 CFU/mL. TSA was used for seeding bacteria in
an incubator at 37 ◦C (Memmert, Schwabach, Germany) in order to calculate the bacteria growth (CFU/mL)
after treatment with the EO-contained molecules.
4.3. Biofilm Formation
S. aureus was grown overnight in TSB until stationary growth phase was reached. At this point,
bacteria were adjusted to 107 CFU/mL and added to a MW96 microplate and incubated at 37 ◦C for
16 h without shaking. After incubation, culture medium was discarded and biofilms were washed
twice with PBS. In order to determine biofilm formation, Calcofluor White Stain (50 µL) was added
to each well and incubated 1 min in the dark at room temperature. After incubation, the stain was
removed and biofilms were washed twice with PBS. Samples were air-dried in the dark to be further
visualized in an inverted fluorescence microscope (Olympus IX81).
To be analyzed by SEM, biofilms were grown on sterile glass slides incubated in a S. aureus
planktonic suspension (107 CFU/mL) at 37 ◦C for 16 h without shaking. Then, biofilms were washed
twice with PBS (0.1 M) and fixed in 2.5% glutaraldehyde for 3 h. Samples were dehydrated through
a series of ethanol solutions (30, 50, 70, 80, 90 and 100%; 15 min, twice). Finally, samples were air-dried
at room temperature and coated with Pt to allow electronic observation. SEM images were acquired in
the energy range of 10–15 keV in an SEM Inspect™ F50 (FEI Co., Hillsboro, OR, USA).
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4.4. Antibacterial Activity
4.4.1. MIC and MBC Determination
Inhibitory and bactericidal concentrations of active EO molecules were tested in two bacteria
cultures, E. coli and S. aureus, following the broth microdilution method. Liquid growth medium
containing an inoculum of 105 CFU/mL and serial concentrations of the EO compounds (0.1–4 mg/mL)
were used. EO compounds were solubilized in culture medium by adding Tween® 80 (1.5–2% v/v)
prior to their serial dilution. Once bacteria suspension was in stationary growth (108–109 CFU/mL),
it was further diluted to ~105 CFU/mL and added to different concentrations (0.01–4 mg/mL) of
the antimicrobial agents. Then, samples were incubated for 24 h at 37 ◦C under shaking (150 rpm).
After incubation, bacterial suspensions were diluted in PBS and spot-plated on TSA plates to count
colonies after incubation at 37 ◦C for 24 h. Positive control (untreated bacteria) and negative control
(chlorhexidine treated bacteria) samples were also tested.
4.4.2. SEM
Bacteria morphology before and after treatment with EO molecules was analyzed by SEM as
we previously reported [54]. Briefly, logarithmic growth phase E. coli and S. aureus bacteria cultures
(~105 CFU/mL) were treated with the selected EO compounds at MIC and MBC values and incubated
overnight at 37 ◦C. Following incubation, samples were spin-dried at 600 g and washed twice in
PBS (0.1 M). Bacteria were fixed in 2.5% glutaraldehyde for 90 min and subsequently filtered and
dehydrated in ethanol solutions series (30, 50, 70, 80, 90, and 100%; twice for 15 min). Finally, samples
were air-dried at room temperature and covered with Pt. SEM micrographs were acquired in a SEM
Inspect F50 equipment (FEI Co., LMA-INA, Zaragoza, Spain).
4.4.3. Flow Cytometry
In order to study the bactericidal mechanism of the different molecules present in EOs, E. coli and
S. aureus bacteria samples (107 CFU/mL) were centrifuged at 4400× g for 10 min and resuspended in
the different compound solutions at MIC and MBC concentrations following the protocols previously
described [39,54]. Control groups (not treated and chlorhexidine treated bacteria) were also analyzed.
All samples were incubated overnight at 37 ◦C. After propidium iodide (25 µg/mL; Sigma-Aldrich,
Munich, Germany) addition, samples were analyzed by flow cytometry in Gallios equipment (Beckman
Coulter Company, Cell Separation and Cytometry Unit, CIBA, IIS Aragon, Zaragoza, Spain).
4.4.4. Confocal Microscopy
The Live/Dead®BacLight™ bacterial viability kit (Molecular Probes, Fisher Scientific, Hampton, USA)
was used to detect bacteria membrane damage. The methodology is based on the double-staining by SYTO9
and propidium iodide as indicated by the manufacturer. Bacteria samples incubated at 24 h (107 CFU/mL)
and treated with the selected EO compounds at MIC were washed in sterile saline solution and further put
in contact with the dye mixture for 15 min in the dark at room temperature. Samples were then mounted
on slides and visualized by confocal microscopy (Leica TCS SP2 Laser Scanning Confocal Microscope,
Microscopy Unit, CIBA, IIS Aragon, Zaragoza, Spain). Control samples were also tested as described above.
4.4.5. Synergy Studies
The Broth Dilution Checkerboard test was used to evaluate the interaction among the three most
promising bactericidal EO molecules determined by the MIC and MBC studies against S. aureus as
previously reported [55]. In brief, a solution containing four times the MBC of each compound was
prepared. By using a MW96 plate and fresh medium, compound A was diluted two-fold in vertical
orientation and compound B was diluted two-fold in horizontal direction. Then, a bacterial suspension
(106 CFU/mL, 100 µL) was added and the plate was incubated overnight at 37 ◦C. After incubation,
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bacteria growth was determined by the resazurin assay. The Fractional Inhibitory Concentration Index
(FICI) of the combination of compounds A and B was calculated according to the following equation:
FICI = FICA + FICB
where
FICA =
MICA in presence o f B
MIC o f A
and FICB =
MICB in presence o f A
MIC o f B
FICI results were classified as synergy (FICI < 0.5), addition (0.5≤ FICI≤ 1), indifference (1 < FICI ≤ 4)
or antagonism (FICI > 4), as previously described [56].
4.4.6. Biofilm Disruption
The effects of EO molecules (0.25–1 mg/mL) to prevent the formation of biofilm and to disrupt an
already formed S. aureus biofilm were studied. EO compounds were added to preformed biofilms and
samples were incubated for 24 h at 37 ◦C without shaking. After incubation, biofilms were disrupted
by sonication (15 min, 200 W; Ultrasons, JP Selecta, Barcelona, Spain). Samples were then diluted and
seeded onto agar plates to count the viable colonies grown after 24 h of incubation at 37 ◦C.
To study the effects of the compounds present in the EOs on biofilm formation, those were added
to bacterial suspensions (107 CFU/mL) in a MW96 microplate and incubated for 16 h at 37 ◦C without
shaking. After incubation, planktonic cells were removed by washing them twice with PBS. Biofilm
samples were then sonicated as described above and serially diluted to be further plated on agar.
Viable bacteria (CFU/mL) were counted after 24 h of incubation at 37 ◦C.
4.4.7. Cell Culture and Cytotoxicity Assays
Human dermal fibroblasts, human epidermal keratinocytes (HaCaT), and THP1 human
monocytes were used to evaluate the cytotoxic effects of EO-based compounds.
Fibroblasts and HaCaT were routinely grown in high-glucose DMEM supplemented with 10% FBS
and antibiotic-antimycotic. Monocytes were cultured in RPMI 1640 supplemented with 10% FBS,
1% HEPES, 1% nonessential amino acids, 0.1% 2-mercaptoethanol 50 mM, 1% sodium pyruvate
100 mM, and antibiotic-antimycotic. Macrophages were obtained by the in vitro differentiation of
monocytes by adding 1 µM PMA to the cell culture. All cell types were grown in a humidified
atmosphere at 37 ◦C and 5% CO2.
The cytotoxicity was determined by measuring cell metabolism through the Blue Cell Viability assay.
Cells were seeded on MW96 microplates and incubated with the tested molecules (0.004–0.125 mg/mL)
for 24 h. Control samples (not treated and chlorhexidine treated) were also analyzed. Then, the reagent
was added (10%) and cells were incubated for 4 h at 37 ◦C. The reduction of the dye by metabolically
active cells was monitored in a microplate reader (Multimode Synergy HT Microplate Reader; Biotek,
Winooski, WI, USA) at 535/590 nm ex/em. Cell viability was determined by interpolation of the emission
data obtained from the treated samples and the control samples (not treated cells, 100% viability).
4.4.8. Statistical Analysis
Results are reported as mean ± SD. The normal distribution of the variables was analyzed by the
Shapiro-Wilk test followed by the U-Mann-Whitney or Student test (StataSE 12 statistical software,
StataCorp LP, Texas, TX, USA). Statistically significant differences among groups were considered
when p ≤ 0.05.
5. Conclusions
Compounds present in EOs including CRV, CIN, and THY exhibit the highest in vitro
antimicrobial activities against E. coli and S. aureus of all the antimicrobials tested. THY showed
the lowest MBC values (0.3 mg/mL) among all of the compounds tested and was the most effective
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bactericide against the Gram-negative and Gram-positive strains evaluated. According to SEM
images, flow cytometry and confocal microscopy bacteria membrane disruption is the bactericidal
mechanism attributable to CRV, CIN, and THY. There was no antagonism between the tested active
compounds, but no synergism was found either; only the CRV-THY combination showed an additive
effect. The presence of those compounds at concentrations above 0.5 mg/mL hinders S. aureus biofilm
formation and also partially eliminates preformed biofilms. The subcytotoxic values of the tested
EO compounds (0.015–0.090 mg/mL) are lower than MICs and MBCs for bacteria but much higher
than chlorhexidine doses (0.004 mg/mL). The presence of those antibacterial compounds at MBC
concentrations would be only three orders of magnitude higher than the subcytotoxic dose in the
worst-case scenario.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/23/6/1399/
s1, Figure S1: Bacteria growth (CFU/mL) for E. coli and S. aureus at MIC values for carvacrol, cinnamaldehyde
and thymol active compounds, Figure S2: Flow cytometry histograms at MBC on S. aureus and E. coli, Figure S3:
S. aureus and E. coli confocal images after treatment with carvacrol, cinnamaldehyde and thymol, Figure S4:
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